A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

BACKGROUND: Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Meindl-Beinker, Nadja M., Betge, Johannes, Gutting, Tobias, Burgermeister, Elke, Belle, Sebastian, Zhan, Tianzuo, Schulte, Nadine, Maenz, Martin, Ebert, Matthias P., Haertel, Nicolai
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419339/
https://ncbi.nlm.nih.gov/pubmed/30871493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5446-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares